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INTRODUCTION
Atopic myelitis (myelitis with atopic diasthesis, AM) is a
disease entity that is characterized by the association between
allergic and central nervous system (CNS) disease, and it is
usually defined as myelitis of an unknown cause with either
1) hyperIgEaemia and mite antigen-specific IgE positivity
or 2) coexistent atopic disease (1). AM was first described by
Kira et al. in 1997, and they reported 4 cervical myelitis pa-
tients with associated hyperIgEaemia and atopic dermatitis
(2). AM has been reported in nearly 100 patients particularly
in Japanese patients, and it is characterized by distinct features
such as 1) stepwise progression and fluctuation of the clinical
course, 2) paresthesia and/or dysesthesia as the predominant
symptoms, 3) the relatively infrequent occurrence of muscle
weakness, 4) T2-high signal intensity lesions on magnetic
resonance imaging (MRI), 5) hyperIgEaemia, 6) mite anti-
gen-specific IgE positivity, 7) mild peripheral blood eosino-
philia, and 8) eosinophilic inflammation on spinal cord biop-
sy (1, 3, 4). Therefore, an allergic mechanism such as cross-
reactivity between environmental allergens and CNS anti-
gens is thought to be important for this condition (5). But
the pathogenesis of the disease is still unclear. 
Toxocariasis is an ubiquitous parasitic infection by Toxo-
cara canis or T. cati in man, the accidental hosts. It is caused
by ingesting eggs in soil or by eating uncooked/undercooked
animal liver or meat containing the infective-stage larvae (6,
7). The larvae hatch in the proximal small intestine, penetrate
the mucosa, migrate into the liver and lung, and then they
enter the systemic circulation till their progress is impeded
(8). They eventually penetrate the capillaries and migrate aim-
lessly into the host tissue. The migrating larvae leave tracks
of hemorrhage, necrosis and inflammatory cells and they in-
duce immune-mediated hypersensitivity reactions that may
lead to clinical manifestations with peripheral blood eosino-
philia and hyperIgEaemia (8). The diagnosis is made by sero-
logic confirmation using the enzyme-linked immunosorbent
assay (ELISA) with Toxocara excretory-secretory antigens (TES-
Ag) (9, 10) or the diagnosis is made, on rare occasions, by tis-
sue biopsy (11). The seroprevalence of toxocariasis in rural
Korean adults was detected to be approximately 5% (12)
although the seroprevalence of toxocariasis varies depending
on the other country (13).
Myelitis due to T. canis is a rare disease. It has been report-
Atopic myelitis is defined as myelitis with atopic diasthesis but the cause is still un-
known. Toxocariasis is one of the common causes of hyperIgEaemia that may lead
to neurologic manifestations. The purpose of this study was to evaluate the sero-preva-
lence of Toxocara specific IgG Ab among the atopic myelitis patients. We evaluat-
ed the medical records of 37 patients with atopic myelitis whose conditions were
diagnosed between March 2001 and August 2007. Among them, the 33 sera were
analyzed for specific serum IgG Ab to Toxocara excretory-secretory antigens (TES).
All of 37 patients had hyperIgEaemia. Specific IgE to D. pteronyssinus and D. farinae
was detected in 22 (64.7%) and 34 (100%) patients, respectively, of the 34 patients.
Thirty-one of 33 patients (93.9%) were found to be positive by TES IgG enzyme-
linked immunosorbent assay (ELISA). Based on the image findings of eosinophilic
infiltrations in the lung and liver, 8 patients had positive results. These results inferred
that the prevalence of toxocariasis was high in patients with atopic myelitis. Our results
suggest that toxocariasis might be an important cause of atopic myelitis and Toxo-
cara ELISA is essential for evaluating the causes of atopic myelitis.
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ed in only about 20 patients (11, 14-26) although toxocari-
asis is a worldwide-occurring parasitic infection. One possi-
ble explanation is that the accurate diagnosis of toxocariasis
is impossible because either the diagnostic methods are not
available or there is a lack of awareness by medical doctors
about toxocariasis. The characteristics of Toxocara myelitis
are; 1) predominant sensory disturbances (Lhermitte’s sign,
paresthesia and hypesthesia) with rare severe motor weakness,
2) high signal intensities on T2-weighted MRI with relatively
mild symptoms, 3) peripheral blood hyperIgEaemia, 4) pe-
ripheral blood eosinophilia, and 5) eosinophilic inflamma-
tion that is noted on tissue biopsy (15, 24). 
Our previous study showed that the prevalence of toxocari-
asis was high (68%) in patients with unknown eosinophilia,
the patients who had a history of raw liver eating had a higher
incidence, and the patients with liver and/or lung involve-
ment were common (6). In the paper, we suggested that the
clinical triad of toxocariasis is unexplained eosinophilia, the
liver or lung nodules on imaging studies, and a history of eat-
ing animal liver can support clinical diagnosis of toxocariasis.
While studying the characteristics of AM patients in Korea,
we found out that most of them had raw food intake histo-
ries which are known to be reservoirs of the encapsulated larva
of T. canis (6). Similar neurological symptoms with predom-
inant sensory disturbance and clinical signs such as periph-
eral blood eosinophilia, hyperIgEaemia, and the similar MRI
findings between AM and Toxocara myelitis lead us to hypoth-
esize that Toxocara myelitis might be an important cause of
AM. The existence of such patients prompted us to study the
prevalence of Toxocara specific IgG Ab among the AM patients
to gain insight into a link between AM and Toxocara myelitis.
MATERIALS AND METHODS
Subjects
We retrospectively analyzed the medical records of 37 pati-
ents with AM who visited our clinic between March 2001
and August 2007. AM was defined as myelitis of unknown
cause with either 1) hyperIgEaemia and mite antigen-specific
IgE positivity, or 2) coexistent atopic disease such as atopic
dermatitis, allergic rhinitis, bronchial asthma and food allergy
as described by Osoegawa et al. (1). The study was approved
by the research ethics committee at the Samsung Medical Cen-
ter, and 33 of the subjects gave a written informed consent.
Methods
The medical records were reviewed for information related
to the clinical data of the patients, including the age at onset,
gender, a history of preceding atopic diseases, a history of raw
food intake that included raw liver, raw meat or raw fresh-
water fish within 6 month of symptom development, mode
of onset, the clinical course, the clinical symptoms and signs,
the location of lesions (MRI lesions), other organ involvements
including the lung and liver (by plain chest radiography, com-
puted tomography, or hepatic sonography), stool examinations,
laboratory findings of peripheral blood eosinophil counts,
serum total IgE and allergen specific IgE levels, the eosino-
philic cationic protein (ECP) levels, parasite ELISA, the Toxo-
cara specific IgG levels, and the cell counts in cerebrospinal
fluid (CSF).
The mode of onset was defined as either acute (reaching
maximum intensity within 1 month) or chronic (reaching
maximum intensity after 1 month). Eosinophilia was defined
as more than 500 cells/μ L in peripheral blood or more than
5% in CSF. The serum total IgE and two common mite anti-
gens, Dermatophagoides pteronyssinus and Dermatophagoides fari-
nae-specific IgE levels were measured using an ImmunoCAP-
250 (Pharmacia & Upjohn Diagnostics AB, Uppsala, Swe-
den). The upper normal limits of the serum total IgE and
the mite antigen-specific IgE levels are 250 U/mL and 0.34
U/mL, respectively. 
Specific IgG antibodies to parasite (Paragonimus, Sparga-
num, Cysticercus, and Clonorchis) in the serum and the CSF
were measured at the Department of Clinical and Laborato-
ry Medicine of Yong-San Hospital, Chung-Ang University
(Seoul, Korea). The serologic diagnosis of Toxocara infection
was done by measuring the specific IgG antibody to T. canis
with a Toxocara ELISA kit (Bordier affinity products, Crissier,
Switzerland) as described previously (7). Total 33 sera were
kept at -70℃ until use. The result was positive when the
absorbance of the sample was higher than the absorbance of
the weak positive control, which meant that the IgG anti-
body concentration against TES Ag was clinically significant.
The immunodiagnosis of toxocariasis by TES IgE Western
blot analysis of the serum was also performed to eliminate
possible cross-reactions. The TES Ag were kindly supplied
from Dr. Sun Huh (Department of Parasitology, College of
Medicine, Hallym University, Chuncheon, Korea). 
All patients had supportive therapy with systemic corticos-
teroid and some had additive albendazole therapy (800 mg/
day for 28 days). The outcome score was determined accord-
ing to a score system (0, complete resolution; 1, near complete
resolution; 2, marked improvement; 3, moderate improve-
ment; 4, minimal improvement; 5, relapse and/or aggrava-
tion). Patients with outcome score 5 were defined as non-res-
ponders and others were defined as responders.
Statistical analysis
The data was analyzed by SAS. The relationships among
the eosinophil counts, the laboratory data and organ involve-
ment were analyzed by Mann-Whitney U test. We performed
Pearson’s correlation analysis, and Spearman’s correlation anal-
ysis for the non-parametric distributions. 1026 J.-Y. Lee, B.-J. Kim, S.-P. Lee, et al.
RESULTS
Patient characteristics and clinical findings
The clinical data is summarized in Table 1. The male/female
ratio was 36:1. The age at onset was 47±13 (Mean±SD) yr
old on average, although it varied from 23 to 74 (median=45
yr), and 20 (55.6%) of the patients were between 20 and 49
yr old. The mean follow-up period was 570±337 days (Mean
±SD, range 133-1,425 days, median 433 days). Out of the
37 subjects, 36 patients (97.3%) had a history of raw food
intake history and 27 patients (73.0%) had eaten raw foods
within 6 months of developing symptoms. For the 33 Toxo-
cara ELISA-available patients, all the patients had a history
of raw food intake and 25 patients (75.8%) had a history of
raw food intake within 6 month of symptom development.
Five patients (13.5%) had a history of close contact with pets.
Atopic diseases were present in 14 (37.8%) of the 37 pati-
ents. The most frequent atopic diseases were allergic rhinitis
(57.0%), atopic dermatitis (28.6%), food allergy (7.2%), and
bronchial asthma (7.2%) in that order. The remaining 23 (62.1
%) patients with both hyperIgEaemia and mite antigen-spe-
cific IgE were considered to have atopic diasthesis. There were
no differences of the clinical data between the patients with
atopic disease and the patients with atopic diasthesis.
The mode of onset was acute in 9 (24.3%) and chronic in
28 (75.7%) of the 37 patients. Stepwise progression and/or
fluctuation of symptoms were seen in 23 (62.2%) and mono-
phasic features were seen in 14 (37.8%) of the 37 AM pati-
ents. The most common initial symptoms were paresthesia
and/or dysesthesia (73.0%) followed by muscle weakness
(24.3%). Paresthesia and/or dysesthesia (94.6%) were also
the most frequently observed symptoms/signs throughout
the entire clinical course and this was followed by sensory
impairment (75.7%), muscle weakness (62.2%), hyperreflex-
ia (51.4%) and gait disturbance (43.2%) although severe mus-
cle weakness (motor power below Grade III) or pathologic
reflexes were infrequent (n=6, 16.2% and n=6, 16.2%, res-
pectively). Autonomic dysfunctions were frequently observed
in 29 (78.4%) of the 37 patients with bladder (93.1%), bowel
(86.2%) and sexual dysfunction (70.0%). 
Variables No. of patients %
History of allergic disease 14 37.8
Allergic rhinitis 8
Atopic dermatitis 4
Food allergy 1
Bronchial asthma 1
History of raw liver/meat
Ever 36 97.3
Within 6 month of symptom 27 73.0
History of intimate animal contact 5 13.5
Mode of onset
Acute 9 24.3
Chronic 28 75.7
Clinical course
Monophasic 14 37.8
Stepwise progression or fluctuating 23 62.2
Initial symptoms
Paresthesia/dysesthesia 27 73.0
Motor weakness 9 24.3
Cranial nerve palsy 1 2.7
Symptoms and signs 
Paresthesia/dysesthesia 35 94.6
Sensory impairment 28 75.7
Hyperreflexia 19 51.4
Autonomic disturbance 29 78.4
Urination 27
Bowel habit 25
Ejaculation 20
Motor weakness 23 62.2
More than motor power grade IV 17
Below motor power grade III 6
Babinski’s sign 6 16.2
Gait disturbance 16 43.2
Table 1. Summary of clinical data from 37 patients with atopic
myelitis
Variables
CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; CT, com-
puted tomography.
No. of patients %
Eosinophilia in peripheral blood 20/37 54.1
HyperIgEaemia 37/37 100.0
Specific IgE to D. pterinyssinus 22/34 64.7
D. farinae 34/34 100.0
Skin prick test result to dust-mite allergens  0/6 0.0
in atopic diasthesis patients
Specific IgG to Paragonimus 0/28
Sparganum 1/28 3.6
Cysticercus 1/28 3.6
Clonorchis 0/28
Toxocara 31/33 93.9
CSF 
Pleocytosis (≥5/μ L) 4/26 15.4
Presence of eosinophils 9/26 34.6
Eosinophilia (≥5%) 8/26 30.8
MRI lesions
Localized lesion 32/36 88.9
Cervical cord 12/32 37.5
Thoracic cord 14/32 43.8
Lumbar cord 1/32 3.1
Cervical and thoracic cord 5/32 15.6
T2-high intensity lesion 31/32 96.9
Gadolinium enhancement 24/32 75.0
Spinal cord swelling 26/32 81.3
Image findings of eosinophilic infiltrations  4/36 11
in lung
Chest radiography 2/36
Chest CT 3/4
Image findings of eosinophilic infiltrations in liver 7/22 32
Hepatic sonography 4/19
Liver CT  4/6
Table 2. Summary of laboratory data from 37 patients with ato-
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Laboratory findings
The laboratory findings are summarized in Table 2. The
initial peripheral blood white blood cell counts were ranged
from 4,640 to 18,050/μ L (median: 7,445/mL) and leukocy-
tosis (>10,000/μ L) was seen in 7 patients (18.9%). The peak
peripheral blood eosinophil counts were ranged from 0 to
8,484/μ L (median: 511/mL). Peripheral blood eosinophilia
(>500/μ L) was detected in 20 (54.1%) of 37 patients and the
degree of eosinophilia was median 915/μ L in these 20 patients.
Of the 31 Toxocara sero-positive patients, peripheral blood eo-
sinophilia was detected in 17 (56.7%) patients and the degree
of eosinophilia was median 1,073/μ L (692/μ L, 1,661/μ L) al-
though 7 of them pretreated with systemic corticosteroids.
Of the 26 patients with CSF analyses, only 4 patients (15.4%)
showed pleocytosis (≥5/μ L), 9 patients (34.6%) showed the
presence of eosinophils, and 8 patients (30.8%) showed CSF
eosinophilia (≥5%). All 37 patients had hyperIgEaemia and
the median level of serum IgE was 937 IU/mL (523 IU/mL,
2,302 IU/mL). Of the 31 Toxocara sero-positive patients, all
had hyperIgEaemia and the median level of serum IgE was
1,226 IU/mL (534 IU/mL, 3,031 IU/mL).
Parasite and Toxocara serologic findings
For the 33 patients who underwent serum TES IgG ELISA,
31 patients (93.9%) had positive values (Mean±SD of ab-
sorbance, 2.02±0.67). Among the 31 Toxocara-seropositive
patients, all had specific IgE to D. farinae and only two of
them (6.5%) showed a positive reaction against cysticercus
and sparganum antigen, respectively. There was significant
correlation between the Toxocara-specific IgG values and the
serum IgE levels (ρ =0.632, P<0.001). Positive ELISA results
for Toxocara were confirmed by IgE western blot with a typi-
cal pattern of Toxocara specific bands in the low molecular
weight fractions in 8 of 11 patients (Fig. 1). Of the 10 patients
who underwent CSF TES IgG ELISA, all had positive values
(Mean±SD of absorbance, 1.90±0.85). 
Fig. 1. IgE binding to TES Antigens on blotting strips. Serum of A,
B were obtained from toxocariasis patients with liver abscess.
Serum C was obtained from AM patient with Toxocara-IgG posi-
tivity. Serum of D, E, and F were obtained from D. farinae specific
allergic rhinitis patients. Lane A, B, and C revealed a typical pat-
tern of Toxocara specific bands in low molecular weight fractions.
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Fig. 2. Radiologic images from 45-yr-old man whose first symptoms were chest tightness and progressive lower extremities weakness.
He used to eat uncooked cow liver one or two times a month. The peripheral blood showed leukocytosis (11,090/μ L) with 33% eosinophils
and hyperIgEaemia (2,724 U/mL). The values of specific IgE to D. pteronyssinus and D. farinae were 1.4 U/mL and 4.98 U/mL, respectively
although he showed negative skin-prick test results to common aeroallergens. The ELISA test for Toxocara canis was strongly positive
(absorbance 2.195). (A-D) Initial transverse CT scan showing a lung nodule with halo sign and multiple low attenuating nodules in the liver.
(E-H) One month follow up transverse CT scan showing migrating nodules in the lung and liver. (I, J) T2-weighted MRI images with high
signal intensity lesions at the cervical spinal cord.
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Radiologic findings
Regarding the spinal cord MRI, 2 patients showed normal
finding and another 2 patients showed bulging discs. Local-
ized spinal cord lesions were detected in 32 of 36 patients
(88.6%) and the thoracic cord (43.8%) was the most frequ-
ently observed lesion, followed by the cervical (37.5%), both
the cervical and thoracic (15.6%) and the lumbar cord (3.1%)
in that order. Thirty-one of 32 patients (96.9%) showed high
signal intensity lesions on the T2-weighted images and 78%
of them showed involvement of more than 2 segments (range,
1-8; median, 2). Twenty-six patients (81.3%) had spinal cord
swelling and 24 patients (75.0%) showed nodular or patchy
contrast enhancement (Fig. 2). 
Based on image findings of eosinophilic infiltrations in the
lung, four of 36 patients (11.1%) had positive results. Among
the 4 patients with positive lung findings, two of 36 patients
who underwent chest radiography showed evidence on the
imaging findings of eosinophilic infiltration while 3 of 4
patients who underwent chest computed tomography (CT)
showed positive results. Based on image findings of eosino-
philic infiltrations in the liver, 7 of 22 patients (31.8%) had
positive results. Among the 7 patients with positive liver
findings, 4 of 19 patients who underwent hepatic sonogra-
phy showed eosinophilic liver abscess findings while 4 of 6
patients who underwent liver CT showed positive results. 
Treatment response
The treatment outcome data are summarized in Table 3.
The post-treatment follow up period was 450±273 days
(Mean±SD). Out of 31 Toxocara myelitis patients, 20 had
additive albendazole treatment. There were no demograph-
ic and biological differences between conventional corticos-
teroid treatment group and additive albendazole treatment
group. Analysis of the results showed a significant decrease
of the clinical score in both groups after treatment but addi-
tional albendazole treatment was more efficient when it was
compared as responder and non-responder (P=0.032) (Fig. 3).
Moreover, early albendazole treatment subgroup (within 1 yr
from symptom development, n=13) had better response in
the clinical score (P=0.015) than late albendazole treatment
subgroup. Serum Toxocara-specific IgG levels were decreased
in both group (each, P=0.001, P=0.042) while serum total
IgE levels were significantly decreased only in the addition-
al albendazole treatment group (each, P=0.013, P=0.139).
But, serum ECP levels were not significantly decreased after
treatment in both groups. 
Improvement of spinal MRI findings (resolution or decrease
of high signal intensities on T2WI were observed in 1 of 3
conventional corticosteroid group and 3 of 5 additional alben-
dazole treatment group.
DISCUSSION
AM is one of the idiopathic transverse myelitis associated
with atopic disease or diasthesis. The stepwise progression
and fluctuation of the symptoms are frequent in AM but the
pathomechanism is still unknown (1). Toxocariasis is one of
the most prevalent parasitic infections in the world, caused
by larval stage of Toxocara spp. It is usually non-fatal disease,
but the larvae can migrate through the CNS system and may
Before 
treatment
After 
treatment
P
Clinical score
Conventional 5 3 0.009
Albendazole 5 3 <0.001
P 0.458 0.162
Total IgE (U/mL)
Conventional 1,346 1,280 0.139
Albendazole 1,017 619 0.013
P 0.447 0.108
ECP (ng/mL)
Conventional 56 15 0.611
Albendazole 22 6.9 0.285
P 0.090 0.245
Toxocara ELISA titer (absorbance)
Conventional 3.23 2.25 0.042
Albendazole 2.86 2.13 0.001
P 0.208 0.546
Table 3. Summary of treatment response from 31 patients with
Toxocara myelitis
Fig. 3. Treatment response. All patients had conventional support-
ive therapy with systemic corticosteroid and some had additive
albendazole therapy. The outcome score was determined accord-
ing to a score system and patients with outcome score 5 were
defined as non-responders. Two of 20 patients in additive alben-
dazole group and 5 of 11 patients in corticosteroid group were
non-responders (P=0.032). 
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ECP, eosinophilic cationic protein; ELISA, enzyme-linked immunosor-
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cause such neurologic manifestations in AM. The frequency
and localization of Toxocara larvae in the spinal cord in hu-
mans are unknown. Following a high dose and repeated in-
fections by T. canis, some larvae can migrate to the spinal cord
and induce local inflammation with immediate-type and de-
layed-type hypersensitivity, along with clinical symptoms.
Accurate diagnosis of toxocariasis is not possible sometimes,
because the diagnostic method is not available worldwide
although increased awareness of this disease. We could infer
that many patients who were diagnosed as having AM might
have Toxocara myelitis.
Our clinical and MRI imaging findings were similar with
those of previously reported in AM except for the difference
in the male preponderance (1). Many Koreans, and especially
the males, have a custom of eating raw animal tissue in their
social life based on the belief that is health-promoting food,
and so the chances of being infected by Toxocara larvae might
be more likely increased in Korean males (6). 
The data presented herein suggested that the Toxocara-sero-
prevalence in AM patients was approximately 94% and the
neuropathological mechanism of AM might be due to neu-
ral involvement by Toxocara larvae if one takes into account:
1) the positive histories of ingesting raw liver/meat, which
is known to be the main risk factor for toxocariasis in adults
(6), 2) the accompanied eosinophilic infiltration in the lung
and liver (27), 3) the positive serology in both sera and CSF
with IgG anti-Toxocara, and some of the patients had this con-
firmed by IgE western blotting using TES antigen, 4) the
relatively higher Toxocara ELISA values (absorbance >1.5)
that are associated with active or recent clinical toxocariasis
(9, 10), 5) the peripheral blood eosinophilia and an increase
in the concentration of serum total IgE (>500 IU/mL), which
are further evidence of recent Toxocara infection (12), 6) the
improvement of signs and symptoms after treatment with
albendazole in several cases in our preliminary study and bet-
ter treatment responses after early additional albendazole treat-
ment in sub-group analysis. 
A diagnosis of toxocariasis is made by detection of anti-
body by using ELISA because the histological proof of Toxo-
cara larvae in tissue is extremely difficult and there is little
serologic cross-reaction between toxocariasis and other hel-
minthiases (12). The diagnostic sensitivity is superior to 90%
and specificity of the reaction is also high. However, an ELISA
kit for this disease is not widely available and it is not capa-
ble of distinguishing between current and past infection. So
when interpreting a serologic result and selecting candidates
for anthelmintics therapy, we feel that the immunologic test
should be accompanied by full history taking and laboratory
tests. Therefore, the food habits of suspected patients should
be assessed and Toxocara myelitis should be suspected in those
AM patients with a positive history of raw animal tissue inges-
tion. Moreover, all our patients had hyperIgEaemia, about
60% of them had peripheral blood eosinophilia, and about
30% of them had eosinophilic liver abscess (27), and these
findings might give us additional help to diagnose toxocari-
asis, although long-standing toxocariasis with no or minor sys-
temic involvement except CNS infection might explain the
lack of a specific immune response in blood or other organs. 
In our study, out of total 11 patients with positive ELISA
results for Toxocara, only 8 patients were confirmed by IgE
western blot with a typical pattern of Toxocara specific bands
in the low molecular weight antigen of 24, 28, 30, and 35
kDa. This discrepancy could have been due either to cross-
reactivity due to helminthic disease other than toxocariasis
or to some patients’ selective protein antigen components
destroyed during the boiling process. The value of addition-
al Western blotting for corroborating serological results can-
not be overstated, but it might be more helpful in cases in
which the TES-ELISA values lie under the cut-off or to rule
out cross-reactivity due to other helminthic diseases as Mag-
naval et al. suggested in their study (28). 
Further investigations needed to determine the association
of Toxocara specific antibody and mite specific antibody. One
possible explanation is that the false positivity of mite spe-
cific antibody due to increased production of the serum total
IgE. This is supported by 1) the negative skin prick test results
in the available 8 AM patients with atopic diasthesis who
showed Toxocara sero-positivity, 2) the relatively low serum
value of specific IgE to D. farinae, in 87% of the 23 atopic
diasthesis patients, less than 10 IU/mL. Allergenic cross-reac-
tivity between the nematode T. canis and the dust mite D.
farinae might also be a possible explanation. Several studies
have suggested there is allergenic cross-reactivity between
Anisakis. simplex and other nematode (29). Allergenic cross-
reactivity between A. simplex and four different dust-mite
species has also been reported (30). Therefore, we investigat-
ed a possible allergenic cross-reactivity between T. canis and
D. farinae. We performed western blotting using TES anti-
gens and whole body extracts of D. farinae in some selected
patients with both atopic diasthesis and Toxocara sero-posi-
tivity. In case of western blotting using whole body extracts
of D. farinae, none of 6 patients showed a typical pattern of
D. farinae specific bands as shown in positive controls with
mite-specific allergic rhinitis. In Toxocara-ELISA inhibition
tests using extracts of D. farinae varying from 1, 10, 100, to
1,000 μ g/mL of concentration, no inhibition was observed
in any of the 2 selected sera. So we concluded that mite-anti-
gen specific IgE positivity in AM patients with Toxocara sero-
positivity is false positive results with increased production
of total IgE, rather than allergenic cross-reactivity between
whole body extracts of D. farinae and TES antigens although
the results are not shown here. 
In summary, our study reveals that there is a high preva-
lence of toxocariasis in patients with atopic myelitis. Taking
a good history and performing Toxocara ELISA should be done
for evaluating the causes of atopic myelitis. Liver or lung nod-
ules seen on imaging studies can support diagnosis of Toxo-
cara myelitis.1030 J.-Y. Lee, B.-J. Kim, S.-P. Lee, et al.
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